Antileukotriene treatment in children with asthma - New patents

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 2, Issue 3, 2008, Pages 202-211

  Iwona, Stelmach ^a   Tomasz, Grzelewski ^a  

^a N Copernicus Regional Hospital   (Poland)

Author keywords

5 lipoxygenase activating protein (FLAP) inhibitors; Asthma; Children; Leukotriene B4 receptor antagonists; New 5 lipoxygenase inhibitors

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; AM 103; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; CYSTEINYLLEUKOTRIENE TYPE 1 RECEPTOR; ETALOCIB; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE A4 HYDROLASE INHIBITOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; PEPTIDOLEUKOTRIENE; PLACEBO; UNCLASSIFIED DRUG; ZILEUTON; 5-LIPOXYGENASE-ACTIVATING PROTEIN; ANTIASTHMATIC AGENT; CARRIER PROTEIN; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE B4 RECEPTOR; MEMBRANE PROTEIN;

ARTICLE; ASTHMA; BIOSYNTHESIS; CHILD HEALTH; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; GROWTH DISORDER; HUMAN; PATENT; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED RELEASE FORMULATION; ANIMAL; CHILD; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CARRIER PROTEINS; CHILD; CYSTEINE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MEMBRANE PROTEINS; PATENTS AS TOPIC; RECEPTORS, LEUKOTRIENE B4;

EID: 61449515626     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221308786241938     Document Type: Article

References (89)

1. Bjermer L. Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol 2007; 120: 1269-1275.
2. Steinke JW, Culp JA. Leukotriene synthesis inhibitors versus antagonists: The Pros and Cons. Curr Allergy Asthma Rep 2007; 7: 126-133.
3. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007; 357: 1841-1854.
4. Massoumi R, Sjölander A. The role of leukotriene receptor signaling in inflammation and cancer. ScientificWorld Journal 2007; 7: 1413-1421.
5. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 123-134.
6. Yoshisue H, Kirkham-Brown J, Healy E, et al. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. J Allergy Clin Immunol 2007; 119: 132-140.
7. Ciana P, Fumagalli M, Trincavelli ML, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; 25: 4615-4627.
8. Hicks A, Monkarsh SP, Hoffman AF, et al. Leukotriene B 4 receptor antagonists as therapeutics for infl ammatory disease: Preclinical and clinical developments. Expert Opin Investig Drugs 2007; 16: 1909-1920.
9. Miyahara N, Miyahara S, Takeda K, et al. Role of the LTB4/BLT1 pathway in allergen-induced airway responsiveness and inflammation. Allergy Int 2006; 55: 91-97.
10. Terawaki K, Yokomizo T, Nagase T, et al. Absence ofleukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 2005; 175: 4217-4225.
11. Miyahara N, Takeda K, Miyahara S, et al. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 2005; 172: 161-167.
12. James AJ, Penrose JF, Cazaly AM, Holgate ST, Sampson AP. Human bronchial fibroblasts express the 5-lipoxygenase pathway. Respir Research 2006; 7: 102.
13. Tager AM, Luster AD. BLT1 and BLT2: The leukotriene B4 receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 123-134.
14. Yokomizo T, Izumi T, Shimizu T. Co-expression of LTB4 receptors in human mononuclear cells. Life Sci 2001; 68: 2207-2212.
15. Shin EH, Lee HY, Bae YS. Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. Biochem Biophys Res Commun 2006; 348: 606-611.
16. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W.The PPAR α-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
17. Mellor EA, Frank M, Soler D, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Nat Acad Sci USA 2003; 100: 11589-11593.
18. Thivierge M, Stankova J, Rola-Pleszczynski M. IL-13 and IL-4 upregulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 2001; 167: 2855-2860.
19. Qui H, Johansson AS, Sjostrom M, et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci USA 2006, 103: 6913-6918.
20. Stelmach I, Bobrowska-Korzeniowska M, Majak P, Stelmach W, Kuna P. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulm Pharmacol Ther 2005; 18: 374-380.
21. Baena-Cagnani C, Rossi GA, Canonica GW. Airway remodelling in children: When does it start? Curr Opin Allergy Clin Immunol 2007; 7: 196-200.
22. Lex C, Zacharasiewicz A, Payne DN, et al. Exhaled breath condensate cysteinyl leukotrienes and airway remodeling in childhood asthma: a pilot study. Respir Res 2006; 7: 63-70.
23. Shibata A, Katsunuma T, Tomikawa M, et al. Increased leukotriene E4 in the exhaled breath condensate of children with mild asthma. Chest 2006; 130: 1718-1722.
24. Rabinovitch N, Zhang L, Gelfand EW. Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol 2006; 118: 635-640.
25. Arriba-Mendez S, Sanz C, Isidoro-Garcia M, et al. 927T>C polymorphism of the cysteinyl-leukotriene type-1 receptor (CYSLTR1) gene in children with asthma and atopic dermatitis. Pediatr Allergy Immunol 2006; 17: 323-328.
26. Stelmach I, Majak P, Jerzynska J, Stelmach W, Kuna P. Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: A randomized pragmatic study. Pediatr Allergy Immunol 2004; 15: 359-364.
27. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109: 257-263.
28. Stelmach I, Majak P, Jerzynska J, Kuna P. The effect of treatment with montelukast on in vitro interleukin-10 production of mononuclear cells of children with asthma. Clin Exp Allergy 2005; 35: 213-220.
29. Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of antiasthma treatment on lung function in children with asthma. Pulm Pharmacol Ther 2007; 20: 691-700.
30. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008; 121: 383-389.
31. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2007; 29: 72-78.
32. Dubé LM, Swanson LJ, Awni W. Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma: Clinical pharmacokinetics and safety. Clin Rev Allergy Immunol 1999; 17: 213-221.
33. Beierschmitt WP, McNeish JD, Griffiths RJ, et al. Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): Studies in rats and 5-LO knockout mice. Toxicol Sci 2001; 63: 15-21.
34. Boot JR, Sweatman WJ, Cox BA, Hutchinson JH. The anti-allergic activity of Benoxaprofen [2-(4-chlorophenyl)-alpha-methyl-5-benzoxazole acetic acid] - a lipoxygenase inhibitor. Int Arch Allergy Appl Immunol 1982; 67: 340-343.
35. Musser JH, Kubrak DM, Chang J, et al. Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters. J Med Chem 1987; 30: 400-405.
36. Park, C., Hae-young, L., Hyeong-kyu, O., Sei-ryang, A., Kyungseop, H., Gyoonhee, K., Joo, H.: WO08035956A1 (2008).
37. Park, C., Hea, Y., Chang, H.W., Yoon, J.H., Ju, H.K.: US20087329682 (2008).
38. Hutchinson, J., Seiders, T.J., Stearns, B.A., Wang, B., Scott, J.M., Troung, Y.P.: WO07087250A2 (2008).
39. Görlitzer K, Fabian J, Jones PG, Frohberg P, Drutkowski G. Pyridazino(3,4-c)quinolines and pyridazino(4,5-c)quinolines - synthesis and investigation of lipoxygenase inhibition. Pharmazie 2002; 57: 362-371.
40. Verma, A.K., Malhotra, S.R., Abhijit, K., Shirumalla, R.: US20080021080A1 (2008).
41. Han, C.K., Joung, K., Yoo, H., Cho, Y.B., Ryu, K.H., Baek, H.Y., Kim, T.S., Jung, I. H., Kwak, W.-J.: WO06046814A1 (2008).
42. Li H, Yuan GD, Jin YH, Li R, Wang L, Wang S. Experimental study on hemostatic effect of flos sophorae and its extracts. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004; 24: 1007-1009.
43. Bandyopadhyay, S., Roy, K.C., Roy, M., Pal, B.C., Bhadra, R., Das, K., Bhattacharaya, S.: EP1414475B1 (2005).
44. Tachibana Y, Kikuzaki H, Lajis NH, Nakatani N. Antioxidative activity of carbazoles from Murraya koenigii leaves. J Agric Food Chem 2001; 49: 5589-5594.
45. Ferguson AD, McKeever BM, Xu S, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007; 317: 510-512.
46. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839-844.
47. Dahlen B, Kumlin M, Ihre E, Zetterström O, Dahlén SE. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAY X1005. Thorax 1997; 52: 342-347.
48. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95: 42-51.
49. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007; 61: 663-676.
50. Chapman KR, Friedman BS, Shingo S, Heyse J, Reiss T, Spector R. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am J Respir Crit Care Med 1994; 149: A215.
51. Storms W, Friedman BS, Zhang J, et al. Treating asthma by blocking the lipoxygenase pathway. Am J Respir Crit Care Med 1995; 151: A377.
52. Internet page accesses May/10/2008: http://www.reuters.com/article/ pressRelease/idUS138569+04-Feb-2008+PRN20080204
53. Ogawa, A., Ujjainwalla, F., Vande Bunte, E.K., Chu, L., Ondeyka, D., Kopka, I., Li, B., Ok, H., Patel, M.J., Xu, J., Sisco, R.: WO08030369A1 (2008).
54. Chen X, Wang S, Wu N, Yang CS. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets 2004; 4: 267-283.
55. Thunnissen MM, Nordlund P, Haeggström JZ. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 2001; 8: 131-135.
56. Sandanayaka, V., Singh, J., Zhao, L., Yu, P., Gurney, M.E.: WO08019302A1 (2008).
57. Sandanayaka, V., Chandrasekar, P., Irvine, C.A., Gurney, M.E.: US20080090839A1 (2008).
58. Sandanayaka, V., Singh, J., Zhou, L.M., Gurney, M.E.: WO07078335A2 (2007).
59. Internet page accesses May/10/2008: http://www.iddb3.com/IDdb3 Drug Alerts © 1997-2007 Thomson Scientific Ltd.
60. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51: 1178 -1184.
61. Internet page accesses May/10/2008: http://www.amirapharm.com/articles/ Jul07-AM103.html Amira Pharmaceuticals press release (16 July 2007).
62. Oishi, Y., Kawano, S., Yokomizo, T.: WO04106317A1 (2004).
63. Oishi, Y., Kawano, S., Yokomizo, T.: US20060194851A1 (2006).
64. Ando K, Tsuji E, Ando Y, et al. Synthesis of 2-, 4-snf 5-(2-alkylcarbamoyl-1- methylninyl)-7-alkyloxybenzo[b]furans and their leukotriene B4 receptor antagonistic activity. Org Biomol Chem 2005; 3: 2129-2139.
65. Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances Proc Natl Acad Sci USA 2000; 97: 6155 -6160.
66. Mchugh D, Mcmaster RS, Pertwee RG, et al. Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors. J Pharm Exp Ther 2006; 316: 955 -965.
67. Nakade, S., Shouno, T., Shimizu, T., Yokomizo, T., Iizuka, Y.: WO05102388A1 (2005).
68. Nakade, S., Shouno, T., Shimizu, T., Yokomizo, T., Iizuka, Y.: EP1745800A1 (2007).
69. Dombroski, M.A., Koch, K., Piscopio, A. D.: US6117874 (1999).
70. Bonnans C, Levy BD. Lipid mediators as agonists for the resolution of acute lung inflammation and injury. Am J Respir Cell Mol Biol 2007; 36: 201-205.
71. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for antiinflammatory receptors. J Exp Med 1997; 185: 1693-1604.
72. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-proteincoupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620-624.
73. Kuroki, Y., Ueno, H., Katsube, T., Kawaguchi, T., Yamaguchi, J., Okanari, E., Tanaka, I., Tanaka, M., Hagihara, M.: US20040180884A1 (2004).
74. Ichikawa, Y., Nishida, T., Nakano, J., Minami, K.-C., Watanuki, M., Suda, M., Nakamura, T.: EP0999209B1 (2006).
75. Friedrich I, Müller-Goymann CC. Characterisation of SRMS and production development of SRMS-based nanosuspensions. Eur J Pharm Biopharm 2003; 56: 111-119.
76. Friedrich I, Reichl S, Müller-Goymann CC. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm 2005; 305: 167-175.
77. Liversidge, G., Jenkins, S., Wertz, C., Bosch, W.H.: US20070065374 (2007).
78. Gurney, M.E., Hakonarson, H.: US20060257481A1 (2006).
79. Lima JJ. Treatment heterogeneity in asthma: Genetics of response to leukotriene modifiers. Mol Diagn Ther 2007; 11: 97-104.
80. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm 2006; 316: 86-92.
81. Takasaki, J., Kamohara, M., Matsumoto, M., Saito, T., Sugimoto, T., Ota, T., Isogai, T., Nishikawa, T., Kawai, Y.: US20077217800 (2007).
82. Anderson, W.H., Edwards, L., Emmett, A.H., Pillai, S., Sprankle, C.S.: US20040162193A1 (2004).
83. Anderson, W.H., Edwards, L.D., Emmett, A. H., Pillai, S., Sprankle, C. S.: US20056939674 (2005).
84. Brunlöf G, Tukukino C, Wallerstedt SM. Individual case safety reports in children in commonly used drug groups - signal detection. BMC Clin Pharmacol 2008 17; 8: 1.
85. Pedersen S, Agertoft L, Williams-Herman D, et al. Placebocontrolled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol 2007; 42: 838-843.
86. Becker AB, Kuznetsova O, Vermeulen J, et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 2006; 96: 800-807.
87. Gaudreault E, Gosselin J. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J Immunol 2008; 180: 6211-6221.
88. Gaudreault E, Gosselin J. Leukotriene B4-mediated release of antimicrobial peptides against cytomegalovirus is BLT1 dependent. Viral Immunol 2007; 20: 407-420.
89. Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis.Am J Respir Crit Care Med 2003; 167: 379-383.